am I the only one who found triple agonist harder than the injections
Slightly embarrassed to be asking this, but: am I the only one who found triple agonist harder than the injections. Stopped at a low step because there was no reason to go further and no data to tell me what further would do. The standing caveat, written out properly because it keeps getting compressed into a…
What is the source for that figure — the published paper or a summary of it?
Removed the escalation schedule. There is no published protocol for members to follow and inventing one here is exactly what this board does not do.
Removed the escalation schedule.
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
small trial, big effect, wide error bars
Same read. The energy-expenditure mechanism is the interesting bit and it is not established in humans at scale.
the phase 2 numbers were striking and they were also 48 weeks in a small population
The muscle cramps profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.